139 related articles for article (PubMed ID: 12770819)
21. Inhibiting HTLV-1 Protease: A Viable Antiviral Target.
Lockbaum GJ; Henes M; Talledge N; Rusere LN; Kosovrasti K; Nalivaika EA; Somasundaran M; Ali A; Mansky LM; Kurt Yilmaz N; Schiffer CA
ACS Chem Biol; 2021 Mar; 16(3):529-538. PubMed ID: 33619959
[TBL] [Abstract][Full Text] [Related]
22. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus.
Wlodawer A; Gustchina A; Reshetnikova L; Lubkowski J; Zdanov A; Hui KY; Angleton EL; Farmerie WG; Goodenow MM; Bhatt D
Nat Struct Biol; 1995 Jun; 2(6):480-8. PubMed ID: 7664111
[TBL] [Abstract][Full Text] [Related]
23. Subsite preferences of retroviral proteinases.
Dunn BM; Gustchina A; Wlodawer A; Kay J
Methods Enzymol; 1994; 241():254-78. PubMed ID: 7854181
[No Abstract] [Full Text] [Related]
24. Evaluations of substrate specificity and inhibition at PR/p3 cleavage site of HTLV-1 protease.
Naka H; Teruya K; Bang JK; Aimoto S; Tatsumi T; Konno H; Nosaka K; Akaji K
Bioorg Med Chem Lett; 2006 Jul; 16(14):3761-4. PubMed ID: 16682197
[TBL] [Abstract][Full Text] [Related]
25. Purification and characterization of human T-cell leukemia virus type I protease produced in Escherichia coli.
Kobayashi M; Ohi Y; Asano T; Hayakawa T; Kato K; Kakinuma A; Hatanaka M
FEBS Lett; 1991 Nov; 293(1-2):106-10. PubMed ID: 1959638
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of retro-inverso modifications of HTLV-1 protease inhibitors containing a hydroxyethylamine isoster.
Tatsumi T; Awahara C; Naka H; Aimoto S; Konno H; Nosaka K; Akaji K
Bioorg Med Chem; 2010 Apr; 18(7):2720-7. PubMed ID: 20226680
[TBL] [Abstract][Full Text] [Related]
27. Characterizing the protonation states of the catalytic residues in apo and substrate-bound human T-cell leukemia virus type 1 protease.
Ma S; Vogt KA; Petrillo N; Ruhoff AJ
Comput Biol Chem; 2015 Jun; 56():61-70. PubMed ID: 25889320
[TBL] [Abstract][Full Text] [Related]
28. Crystal structures of inhibitor complexes of human T-cell leukemia virus (HTLV-1) protease.
Satoh T; Li M; Nguyen JT; Kiso Y; Gustchina A; Wlodawer A
J Mol Biol; 2010 Aug; 401(4):626-41. PubMed ID: 20600105
[TBL] [Abstract][Full Text] [Related]
29. Pepstatin-insensitive carboxyl proteinases from prokaryotes. Catalytic residues and substrate specificities.
Oda K; Takahashi S; Ito M; Dunn BM
Adv Exp Med Biol; 1998; 436():349-53. PubMed ID: 9561241
[No Abstract] [Full Text] [Related]
30. Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors.
Nguyen JT; Zhang M; Kumada HO; Itami A; Nishiyama K; Kimura T; Cheng M; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2008 Jan; 18(1):366-70. PubMed ID: 18006315
[TBL] [Abstract][Full Text] [Related]
31. Evaluating a Retro-Inverso Type Inhibitor of HTLV-1 Protease as a Competitive Inhibitor.
Awahara C; Oku D; Kobayashi K; Hattori Y
Chem Pharm Bull (Tokyo); 2024; 72(3):309-310. PubMed ID: 38479891
[TBL] [Abstract][Full Text] [Related]
32. A comparative study of HIV-1 and HTLV-I protease structure and dynamics reveals a conserved residue interaction network.
Rücker P; Horn AH; Meiselbach H; Sticht H
J Mol Model; 2011 Oct; 17(10):2693-705. PubMed ID: 21279524
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of activity of the protease from bovine leukemia virus.
Ménard A; Leonard R; Llido S; Geoffre S; Picard P; Berteau F; Precigoux G; Hospital M; Guillemain B
FEBS Lett; 1994 Jun; 346(2-3):268-72. PubMed ID: 8013645
[TBL] [Abstract][Full Text] [Related]
34. Kinetic characterization of newly discovered inhibitors of various constructs of human T-cell leukemia virus-1 (HTLV-1) protease and their effect on HTLV-1-infected cells.
Demir A; Oguariri RM; Magis A; Ostrov DA; Imamichi T; Dunn BM
Antivir Ther; 2012; 17(5):883-92. PubMed ID: 22436331
[TBL] [Abstract][Full Text] [Related]
35. Beta-secretase as a therapeutic target for inhibitor drugs.
Ghosh AK; Hong L; Tang J
Curr Med Chem; 2002 Jun; 9(11):1135-44. PubMed ID: 12052177
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties.
Zhang M; Nguyen JT; Kumada HO; Kimura T; Cheng M; Hayashi Y; Kiso Y
Bioorg Med Chem; 2008 May; 16(10):5795-802. PubMed ID: 18400502
[TBL] [Abstract][Full Text] [Related]
37. Identification of the RT-RH/IN cleavage site of HTLV-I.
Mariani VL; Shuker SB
Biochem Biophys Res Commun; 2003 Jan; 300(2):268-70. PubMed ID: 12504078
[TBL] [Abstract][Full Text] [Related]
38. Efficient expression and rapid purification of human T-cell leukemia virus type 1 protease.
Ding YS; Owen SM; Lal RB; Ikeda RA
J Virol; 1998 Apr; 72(4):3383-6. PubMed ID: 9525666
[TBL] [Abstract][Full Text] [Related]
39. Molecular modeling of the HIV-2 protease.
Gustchina A; Weber IT; Wlodawer A
Adv Exp Med Biol; 1991; 306():549-53. PubMed ID: 1812757
[No Abstract] [Full Text] [Related]
40. Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease.
Lin YC; Beck Z; Lee T; Le VD; Morris GM; Olson AJ; Wong CH; Elder JH
J Virol; 2000 May; 74(10):4710-20. PubMed ID: 10775609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
